Oncogenic PKC-ι activates Vimentin during epithelial-mesenchymal transition in melanoma; a study based on PKC-ι and PKC-ζ specific inhibitors

Documenti analoghi

• Two novel atypical PKC inhibitors; ACPD and DNDA effectively mitigate cell proliferation and epithelial to mesenchymal transition of metastatic melanoma while inducing apoptosis
  di: Ratnayake, Wishrawana S., et al.
  Pubblicazione: (2017)
• Analysis of PKC-ζ protein levels in normal and malignant breast tissue subtypes
  di: Smalley, Tracess, et al.
  Pubblicazione: (2019)
• Atypical PKCs activate Vimentin to facilitate prostate cancer cell motility and invasion
  di: Ratnayake, Wishrawana S., et al.
  Pubblicazione: (2021)
• Preclinical testing of 5-amino-1-((1R,2S,3S,4R)-2,3-dihydroxy-4-methylcyclopentyl)-1H-imidazole-4-carboxamide: a potent protein kinase C-ι inhibitor as a potential prostate carcinoma therapeutic
  di: Apostolatos, André H., et al.
  Pubblicazione: (2019)
• Inhibition of atypical protein kinase C-ι effectively reduces the malignancy of prostate cancer cells by downregulating the NF-κB signaling cascade
  di: Apostolatos, André H., et al.
  Pubblicazione: (2018)